Clinical trials: Malignancies Multiple
Non-small Cell Lung Cancer
A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
This is a randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial to evaluate the efficacy and safety of Fruquintinib plus best supportive care in patients with advanced non-squamous non-small cell lung…
- Trial name
- NCT02590965
- Testing
- Fruquintinib
- Where
- 12 sites in China
- Volunteers
- 91 people
- Sponsor
- Hutchison Medipharma Limited
Locally Advanced Solid Tumor, Metastatic Tumor
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
The goal of this clinical trial is to test the safety of TST003 in patients with cancer. The main question[s] it aims to answer are: What is the recommended dose patients can safely receive? How long does this drug remain in the…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
- Trial name
- NCT05731271
- Testing
- TST003
- Where
- 3 sites in United States
- Volunteers
- 111 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Relapsed or Refractory Multiple Myeloma (RRMM)
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma
- Trial name
- NCT07579234
- Testing
- F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd)
- Where
- China
- Volunteers
- 261 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Adult T-cell Leukemia-Lymphoma
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
The purpose of this study is to estimate the overall response rate of subjects with relapsed or refractory Adult T-cell Leukemia-Lymphoma (ATL).
- Trial name
- NCT01626664
- Testing
- KW-0761, Pralatrexate, gemcitabine plus oxaliplatin
- Where
- 20 sites in United States, Belgium and 4 more
- Volunteers
- 71 people
- Sponsor
- Kyowa Kirin, Inc.
Neoplasms
A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors
This study will determine the maximum tolerated dose and the optimal associated 4 weekly dosing schedule of RO5045337, administered as monotherapy in patients with advanced solid tumors.
- Trial name
- NCT00559533
- Testing
- RO5045337
- Where
- 7 sites in United States, France
- Volunteers
- 106 people
- Sponsor
- Hoffmann-La Roche
Laparoscopy, Tissue Adhesion, Surgery-Induced
The Efficacy and Safety of Medicurtain® in Patients With Total Laparoscopic Hysterectomy (Pivotal Study)
This study was designed to assess the safety and efficacy of MEDICURTAIN. Patients who underwent total laparoscopic hysterectomy were randomly assigned either into Medicurtain® treatment group or non-treatment control group.
- Conditions
- Laparoscopy, Tissue Adhesion, Surgery-Induced, Leiomyoma of the Uterine Body
- Trial name
- NCT04672421
- Testing
- Medicurtain®
- Where
- South Korea
- Volunteers
- 107 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Locally Recurrent and Metastatic Breast Cancer
Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer
This open-label, dose-finding, multi-center study is designed to determine the safety and the maximum tolerated dose of AMG 706 given once daily in combination with either weekly paclitaxel (Arm A) or once-every-3 week docetaxel…
- Trial name
- NCT00322400
- Testing
- Docetaxel, Paclitaxel, AMG 706
- Volunteers
- 46 people
- Sponsor
- Amgen
Tuberous Sclerosis Complex
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
The purpose of this study is to evaluate the long-term safety in patients with TSC and refractory seizures who are currently receiving everolimus treatment in the Novartis-sponsored EXIST-3 study and who are determined to be…
- Trial name
- NCT02962414
- Testing
- everolimus
- Where
- 67 sites in United States, Australia and 16 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Solid Advanced Tumor
Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.
This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of the anti-EGFR/c-Met bispecific antibody MCLA-129 in combination with Ensartinib hydrochloride in…
- Trial name
- NCT07448116
- Testing
- MCLA-129, Ensartinib
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Uveal Melanoma
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic…
- Trial name
- NCT02601378
- Testing
- LXS196, LXS196 and HDM201
- Where
- 6 sites in United States, Australia and 4 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed or Refractory Multiple Myeloma
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the…
- Trial name
- NCT07681596
- Testing
- AZD4045, Daratumumab, Aldesleukin
- Where
- 12 sites in United States, Australia
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
ccRCC, Renal Cell Carcinoma (Kidney Cancer)
Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC
Multicenter Phase 2A study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC).
- Conditions
- ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic
- Trial name
- LUTEON ATLAS (NCT07870746)
- Testing
- 177Lu-TLX250
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Thyroid Cancer
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474…
- Trial name
- NCT00410761
- Testing
- ZD6474 (Vandetanib)
- Where
- 127 sites in United States, Australia and 22 more
- Volunteers
- 331 people
- Sponsor
- Genzyme, a Sanofi Company
Carcinoma, Midline
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
This study is divided into two parts; Part 1 of the study is a dose escalation phase to select the recommended dose for Part 2 based on the safety, pharmacokinetic, and pharmacodynamic profiles observed after oral administration…
- Trial name
- NCT01587703
- Testing
- GSK525762
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 196 people
- Sponsor
- GlaxoSmithKline
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Lymphoma
BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have refractory…
- Trial name
- NCT00039156
- Testing
- ortataxel
- Where
- 15 sites in United States, Canada
- Sponsor
- Theradex
Multiple Myeloma
A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma
The purpose of this study is to describe the safety and effect of ATN-224 in combination with bortezomib (Velcade®) in patients with Multiple Myeloma who are relapsed from or refractory to bortezomib.
- Trial name
- NCT00352742
- Testing
- ATN-224 + bortezomib
- Where
- 10 sites in United States
- Volunteers
- 46 people
- Sponsor
- Attenuon
Multiple Myeloma, Myeloma
FT576 in Subjects With Multiple Myeloma
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
- Trial name
- NCT05182073
- Testing
- FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine
- Where
- 14 sites in United States
- Volunteers
- 31 people
- Sponsor
- Fate Therapeutics
Multiple Sclerosis
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
The planned study will be a prospective, non-interventional, observational cohort study using the structure of a registry. Medication usage behavior will be observed for 6 months, while documentation behavior on the wellness…
- Trial name
- PROmyBETAapp (NCT03134573)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046), Betaconnect auto-injector, myBETAapp
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Bayer
EGFR T790M Mutation Positive NSCLC
AZD9291 US Expanded Access Program
To provide access to AZD9291 for adult patients with advanced/metastatic, epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.
- Trial name
- NCT02451852
- Testing
- AZD9291
- Where
- 32 sites in United States
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.